Hexagon Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Buy
+1,107
New +$1.12M 0.15% 64
2025
Q2
Sell
-823
Closed -$680K 999
2025
Q1
$680K Sell
823
-35
-4% -$29.1K 0.13% 77
2024
Q4
$663K Buy
858
+155
+22% +$128K 0.12% 79
2024
Q3
$623K Sell
703
-41
-6% -$36.9K 0.12% 78
2024
Q2
$673K Buy
744
+24
+3% +$19.2K 0.15% 75
2024
Q1
$560K Buy
720
+81
+13% +$57.6K 0.12% 88
2023
Q4
$372K Buy
639
+51
+9% +$29.8K 0.09% 116
2023
Q3
$316K Sell
588
-47
-7% -$24.2K 0.08% 117
2023
Q2
$298K Sell
635
-5
-0.8% -$2.1K 0.08% 119
2023
Q1
$220K Buy
640
+7
+1% +$2.36K 0.06% 151
2022
Q4
$232K Buy
633
+28
+5% +$9.93K 0.07% 139
2022
Q3
$196K Buy
605
+60
+11% +$19K 0.06% 146
2022
Q2
$177K Sell
545
-198
-27% -$59.4K 0.05% 180
2022
Q1
$213K Sell
743
-47
-6% -$12.1K 0.06% 176
2021
Q4
$218K Sell
790
-93
-11% -$23.6K 0.06% 174
2021
Q3
$204K Buy
883
+83
+10% +$20.5K 0.06% 156
2021
Q2
$184K Sell
800
-100
-11% -$20.1K 0.05% 163
2021
Q1
$168K Sell
900
-560
-38% -$110K 0.05% 152
2020
Q4
$246K Sell
1,460
-70
-5% -$10.5K 0.07% 109
2020
Q3
$201K Buy
+1,530
New +$237K 0.06% 112

Other funds holding LLY

Hexagon Capital Partners's LLY Position: Q1 2026 in Review

Hexagon Capital Partners opened a new position in Eli Lilly (LLY) in Q1 2026: 1,107 shares worth $1.02M. The stake represents 0.15% of the portfolio and ranks #64 among its holdings. This is a return to the name: Hexagon Capital Partners previously reported a position in LLY as recently as Q1 2025.

Hexagon Capital Partners first reported a position in LLY in Q3 2020 and has held it in 20 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Hexagon Capital Partners held 1,107 shares of Eli Lilly worth $1.02M as of Q1 2026.
  • Eli Lilly was a new Hexagon Capital Partners position in Q1 2026.
  • Eli Lilly made up 0.15% of Hexagon Capital Partners's portfolio in Q1 2026, its #64 holding.
  • Hexagon Capital Partners first reported a position in Eli Lilly in Q3 2020 and has held it in 20 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Hexagon Capital Partners's 13F filing for Q1 2026, filed 5 May 2026.